Subject(s)
Carpal Joints , Immunoglobulin Light-chain Amyloidosis , Joint Diseases/diagnosis , Multiple Myeloma/diagnosis , Positron Emission Tomography Computed Tomography/methods , Antirheumatic Agents/administration & dosage , Biopsy, Fine-Needle/methods , Bortezomib/administration & dosage , Carpal Joints/diagnostic imaging , Carpal Joints/pathology , Clinical Deterioration , Diagnosis, Differential , Disease Progression , Fatal Outcome , Female , Humans , Immunoglobulin Light-chain Amyloidosis/diagnosis , Immunoglobulin Light-chain Amyloidosis/immunology , Immunoglobulin Light-chain Amyloidosis/physiopathology , Immunoglobulin Light-chain Amyloidosis/therapy , Joint Diseases/etiology , Joint Diseases/immunology , Joint Diseases/physiopathology , Magnetic Resonance Imaging/methods , Middle Aged , Prednisolone/administration & dosageABSTRACT
Renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.
Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Kidney Neoplasms/diagnostic imaging , Positron-Emission Tomography , Tomography, X-Ray Computed , Adult , Angiogenesis Inhibitors/therapeutic use , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/pathology , Female , Fluorodeoxyglucose F18 , Humans , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Middle Aged , Multimodal Imaging , Neoplasm Metastasis , RadiopharmaceuticalsABSTRACT
Antiandrogen therapy alone or combined with radical therapy is the first choice in diagnosis and recurrence of patients with metastatic prostate cancer. However, patients on androgen deprivation frequently show treatment resistance. In recent years, new treatments for metastatic castration-resistant prostate cancer have been developed. Clinical studies with docetaxel have shown its usefulness for first-line therapy, and different therapeutic algorithms with second-line drugs like abiraterone or cabazitaxel have also been proposed. Sequential metabolic study with PET/CT imaging with ¹¹C-choline may be important for assessing the right moment for administration each one of the therapeutic options.
